Burton DR - Search Results

1

2G12-expressing B cell lines may aid in HIV carbohydrate vaccine design strategies.

Doores KJ, Huber M, Le KM, Wang SK, Doyle-Cooper C, Cooper A, Pantophlet R, Wong CH, Nemazee D, Burton DR. Doores KJ, et al. Among authors: burton dr. J Virol. 2013 Feb;87(4):2234-41. doi: 10.1128/JVI.02820-12. Epub 2012 Dec 5. J Virol. 2013. PMID: 23221565 Free PMC article.

2

Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.

Roben P, Moore JP, Thali M, Sodroski J, Barbas CF 3rd, Burton DR. Roben P, et al. Among authors: burton dr. J Virol. 1994 Aug;68(8):4821-8. doi: 10.1128/JVI.68.8.4821-4828.1994. J Virol. 1994. PMID: 7518527 Free PMC article.

3

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody.

Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, Parren PW, Sawyer LS, Hendry RM, Dunlop N, Nara PL, et al. Burton DR, et al. Science. 1994 Nov 11;266(5187):1024-7. doi: 10.1126/science.7973652. Science. 1994. PMID: 7973652

4

Protection of nude mice by passive immunization with a type-common human recombinant monoclonal antibody against HSV.

Sanna PP, De Logu A, Williamson RA, Hom YL, Straus SE, Bloom FE, Burton DR. Sanna PP, et al. Among authors: burton dr. Virology. 1996 Jan 1;215(1):101-6. doi: 10.1006/viro.1996.0011. Virology. 1996. PMID: 8553581 Free article.

5

In vitro antigen challenge of human antibody libraries for vaccine evaluation: the human immunodeficiency virus type 1 envelope.

Parren PW, Fisicaro P, Labrijn AF, Binley JM, Yang WP, Ditzel HJ, Barbas CF 3rd, Burton DR. Parren PW, et al. Among authors: burton dr. J Virol. 1996 Dec;70(12):9046-50. doi: 10.1128/JVI.70.12.9046-9050.1996. J Virol. 1996. PMID: 8971041 Free PMC article.

6

Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design.

Parren PW, Gauduin MC, Koup RA, Poignard P, Fisicaro P, Burton DR, Sattentau QJ. Parren PW, et al. Among authors: burton dr. Immunol Lett. 1997 Jun 1;57(1-3):105-12. doi: 10.1016/s0165-2478(97)00043-6. Immunol Lett. 1997. Corrected and republished in: Immunol Lett. 1997 Jul;58(2):125-32. doi: 10.1016/s0165-2478(97)00109-0 PMID: 9232434 Corrected and republished. Review.

7

Erratum to "Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design".

Parren PW, Gauduin MC, Koup RA, Poignard P, Sattentau QJ, Fisicaro P, Burton DR. Parren PW, et al. Among authors: burton dr. Immunol Lett. 1997 Jul;58(2):125-32. doi: 10.1016/s0165-2478(97)00109-0. Immunol Lett. 1997. PMID: 9271324 Review.

8

A vaccine for HIV type 1: the antibody perspective.

Burton DR. Burton DR. Proc Natl Acad Sci U S A. 1997 Sep 16;94(19):10018-23. doi: 10.1073/pnas.94.19.10018. Proc Natl Acad Sci U S A. 1997. PMID: 9294155 Free PMC article. Review.

9

Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity.

Parren PW, Mondor I, Naniche D, Ditzel HJ, Klasse PJ, Burton DR, Sattentau QJ. Parren PW, et al. Among authors: burton dr. J Virol. 1998 May;72(5):3512-9. doi: 10.1128/JVI.72.5.3512-3519.1998. J Virol. 1998. PMID: 9557629 Free PMC article.

10

Why do we not have an HIV vaccine and how can we make one?

Burton DR, Moore JP. Burton DR, et al. Nat Med. 1998 May;4(5 Suppl):495-8. doi: 10.1038/nm0598supp-495. Nat Med. 1998. PMID: 9585194 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

669 results

Search Page

Filters